Clinical Trial Update: Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating subcutaneous Exendin(9-39) for efficacy, tolerability, and pharmacokinetics in patients with post-bariatric hypoglycemia; stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-bariatric Hypoglycemia

Drugs mentioned

• Exendin 9-39 (exendin-9-39)

Snippet

Sponsor: Tracey McLaughlin | Conditions: Post Bariatric Hypoglycemia | Phase 2 | Status: COMPLETED | Results posted: 2020-08-14